肌少症是一種以肌肉質量、力量和功能下降為特徵的綜合症狀。肌少症一般又可分類為原發性及次發性兩大類。原發性的肌少症為無 法診斷出特定原因，僅僅因為年紀老化造成的肌肉量減少。次發性肌 少症的原因則較複雜，包括:活動力下降導致運動量不足(例如:長 期臥床、失能)、疾病之併發症(例如:嚴重器官衰竭、癌症、內分 泌疾病)、以及營養不良(含攝取不足、吸收不良或藥物造成的厭食)。 大多數肌少症由複合疾病或風險因子所導致，並非單一病因或病理所 能解釋。一般認為適當的介入與治療能夠延緩或改變因年紀老化造成 肌肉量流失的不良影響。而由癌症所引起，包含肌肉萎縮在內的複合症狀則稱為癌症惡病 質，直接或間接造成癌症病人的生命流逝與生命品質下降。目前針對 癌症惡病質的臨床處置，多以營養補充搭配適當運動訓練。肌肉營養 的補充主要為蛋白質，若無慢性腎臟疾病者，依體重建議攝取蛋白 質，平均分於各餐食。建議的運動形式以有氧運動、漸進式阻力訓練 為主。但結論而言目前並無有效的藥物治療方法。本研究嘗試以動物 實驗測試由常用於肌少症的保健營養原料組成之產品，在不同劑量下 減緩肌肉萎縮作用的功效與其機制之研究。 Sarcopenia is a syndrome characterized by decreased muscle mass, strength, and function. Sarcopenia can generally be classified into two categories: primary and secondary. Primary sarcopenia is the loss of muscle mass due to aging without a specific cause that can be diagnosed. The causes of secondary sarcopenia are more complex and include: decreased activity leading to insufficient physical activity (e.g. prolonged bed rest, disability), complications of disease (e.g. severe organ failure, cancer, endocrine disease), and malnutrition (Includes anorexia due to insufficient intake, malabsorption, or drugs). Most sarcopenia is causedby a combination of diseases or risk factors, not explained by a single etiology or pathology. Appropriate interventions and treatments are generally believed to delay or modify the adverse effects of age-related loss of muscle mass.The complex symptoms including muscle atrophy caused by cancer are called cancer cachexia, which directly or indirectly lead to the loss of life and the decline of life quality of cancer patients. At present, the clinical treatment of cancer cachexia is mostly based on nutritional supplements and appropriate exercise training. Muscle nutrition is mainly supplemented with protein. If there is no chronic kidney disease, the recommended intake of protein is based on body weight, which is equally divided into each meal. The recommended form of exercise is mainly aerobic exercise and progressive resistance training. However, there is currently no effective drug treatment method. This research attempts to use animal experiments to test the efficacy and mechanism of products composed of health-care nutritional raw materials commonly used in sarcopenia at different doses to reduce muscle atrophy.
